Compare DexCom, Inc. (DXCM) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Innodata Inc — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.79B), while Innodata Inc trades at $62.79 (market cap $2.05B). The key difference: DexCom, Inc. is far larger — about 16.5× Innodata Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | INOD | |
|---|---|---|
Market Cap | $33.79B | $2.05B |
Sector | Health | Technology |
52-Week High | $89.53 | $121.50 |
52-Week Low | $54.84 | $34.45 |
Enterprise Value | $33.24B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
INOD trades at $62.26, up 0.06% on the day, with a bullish technical signal supported by oscillators and strong momentum indicators. The company reported robust Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and margin expansion. Analyst consensus is bullish with a $130 price target, reflecting optimism around AI-driven growth and profitability improvements.
Outlook remains positive due to accelerating AI demand and operational leverage, though the stock's premium valuation (P/E 48.62) poses a risk if growth moderates. Key opportunities include continued AI adoption and customer diversification, while risks involve execution challenges and competitive pressures in the AI services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
